RxDoctor Payments Data

Anna Shender

Internal Medicine · Stamford, CTNPI 1083794812

Payments from drug & device makers

$1,279in general payments, 2019–2025

Across 22 payments — averaging $58.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$429
  • AbbVie$341
  • AstraZeneca$307
  • Boehringer Ingelheim$117
  • Galderma Laboratories, L.p.$41
  • Lilly USA, LLC$30
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$1,279100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,279 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$29,882
Medicare patients
48
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$32,848
FarxigaDapagliflozin Propanediol28$30,184
Rosuvastatin Calcium105$2,019
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid13$1,673
Metoprolol Succinate71$1,515
SynthroidLevothyroxine Sodium12$1,353
Levothyroxine Sodium56$803
Atorvastatin Calcium57$655
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide18$612
Losartan Potassium35$444
Sertraline Hcl12$433
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide23$326
Raloxifene Hcl21$322
Tamsulosin Hcl11$298
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid13$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$429$32,84815 claims
AstraZenecaFarxiga$307$30,18428 claims
AbbVieSynthroid$341$1,35312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Stamford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →